SP2 DISCREPANCY IN HEALTH STATE UTILITY VALUES BETWEEN COST-UTILITY ANALYSIS AND REFERENCED ORIGINAL HEALTH UTILITY STUDIES IN CARDIOVASCULAR DISEASE: A REGISTRY-BASED ANALYSIS

Background. Treatment options in oncology are rapidly advancing, and public payer systems are increasingly under pressure to adopt new but expensive cancer treatments. Cost-utility analyses (CUAs) are used to estimate the relative costs and effects of competing interventions, where health outcomes are measured using quality-adjusted life years (QALYs). Health state utility values (HSUVs) are used to reflect health-related quality of life or health status in the calculation of QALYs. To support reimbursement agencies in the appraisal of oncology drug submissions, which typically include a CUA component, we have proposed a systematic literature review of published HSUV estimates in the field of oncology. Methods. The following databases will be searched: MEDLINE, EMBASE, EconLit, and CINAHL. A team of reviewers, working independently and in duplicate, will evaluate abstracts and full-text publications for eligibility against broad inclusion criteria. Studies using a direct, indirect, or combination approach to eliciting preferences related to cancer or cancer treatments are eligible. Data extraction will capture details of study methodology, participants, health states, and corresponding HSUVs. We will summarize our findings with descriptive analyses at this stage. A pilot review in thyroid cancer is presented to illustrate the proposed methods. Discussion. This systematic review will generate a comprehensive summary of the oncology HSUV literature. As a component of the Health Utility Book (HUB) project, we anticipate that this work will assist both health economic modelers as well as critical reviewers in the development and appraisal of CUAs in oncology.

Download Full-text

The impact of multiple sclerosis severity on health state utility values: Evidence from Australia

Multiple Sclerosis Journal ◽

10.1177/1352458516672014 ◽

2016 ◽

Vol 23 (8) ◽

pp. 1157-1166 ◽

Cited By ~ 13

Author(s):

Hasnat Ahmad ◽

Bruce V Taylor ◽

Ingrid van der Mei ◽

Sam Colman ◽

Beth A O’Leary ◽

...

Keyword(s):

Multiple Sclerosis ◽

Disease Severity ◽

Severe Disease ◽

Health Utility ◽

Health State Utility ◽

Health State ◽

Utility Values ◽

Health State Utility Values ◽

Economic Analyses ◽

The Impact

Background: The measurement of health state utility values (HSUVs) for a representative sample of Australian people with multiple sclerosis (MS) has not previously been performed. Objectives: Our main aim was to quantify the HSUVs for different levels of disease severities in Australian people with MS. Method: HSUVs were calculated by employing a ‘judgement-based’ method that essentially creates EQ-5D-3L profiles based on WHOQOL-100 responses and then applying utility weights to each level in each dimension. A stepwise linear regression was used to evaluate the relationship between HSUVs and disease severity, classified as mild (Expanded Disability Status Scale (EDSS) levels: 0–3.5), moderate (EDSS levels: 4–6) and severe (EDSS levels: 6.5–9.5). Results: Mean HSUV for all people with MS was 0.53 (95% confidence interval (CI): 0.52–0.54). Utility decreased with increasing disease severity: 0.61 (95% CI: 0.60–0.62), 0.51 (95% CI: 0.50–0.52) and 0.40 (95% CI: 0.38–0.43) for mild, moderate and severe disease, respectively. Adjusted differences in mean HSUV between the three severity groups were statistically significant. Conclusion: For the first time in Australia, we have quantified the impact of increasing severity of MS on health utility of people with MS. The HSUVs we have generated will be useful in further health economic analyses of interventions that slow progression of MS.

Download Full-text

PCN42 THE HEALTH UTILITY BOOK (HUB): TOWARD A CENTRALIZED, SYSTEMATIC APPROACH TO THE IDENTIFICATION, APPRAISAL, AND USE OF HEALTH STATE UTILITY VALUES FOR REIMBURSEMENT DECISION MAKING

Value in Health ◽

10.1016/j.jval.2019.04.166 ◽

2019 ◽

Vol 22 ◽

pp. S63-S64

Author(s):

F. Xie ◽

M. Zoratti ◽

K. Chan ◽

D. Husereau ◽

M. Krahn ◽

...

Keyword(s):

Decision Making ◽

Systematic Approach ◽

Health Utility ◽

Reimbursement Decision ◽

Health State Utility ◽

Health State ◽

Utility Values ◽

Health State Utility Values

Download Full-text

PCN41 THE HEALTH UTILITY BOOK (HUB): A REGISTRY OF HEALTH STATE UTILITY VALUES IN ONCOLOGY

Value in Health ◽

10.1016/j.jval.2019.04.165 ◽

2019 ◽

Vol 22 ◽

pp. S63

Author(s):

M. Zoratti ◽

T. Zhou ◽

K. Chan ◽

O. Levine ◽

M. Krahn ◽

...

Keyword(s):

Health Utility ◽

Health State Utility ◽

Health State ◽

Utility Values ◽

Health State Utility Values

Download Full-text

Meta-analysis of health state utility values measured by EuroQol 5-dimensions (EQ5D) questionnaire in Chinese women with breast cancer

BMC Cancer ◽

10.1186/s12885-021-09140-5 ◽

2022 ◽

Vol 22 (1) ◽

Author(s):

Tamlyn Rautenberg ◽

Brent Hodgkinson ◽

Ute Zerwes ◽

Martin Downes

Keyword(s):

Breast Cancer ◽

Random Effects ◽

Chinese Women ◽

Meta Analysis ◽

Cost Utility ◽

Health State Utility ◽

First Year ◽

Health State ◽

Utility Values ◽

Health State Utility Values

Abstract Background To synthesise EQ5D health state utility values in Chinese women with breast cancer for parameterising a cost utility model. Methods Eligible studies had to report health state utility values measured by EQ-5D in Chinese women diagnosed with breast cancer. Risk of bias was assessed using the Newcastle Ottawa Scale (NOS). Data from single arm studies was pooled using meta-analysis of single proportions to provide overall point estimates and 95% confidence intervals for fixed and random effects models using the inverse variance and Der Simonian-Laird methods respectively. Heterogeneity was evaluated using the I2 statistic and sensitivity analysis and meta-regression were conducted. Results Five papers were included, when all studies were combined (n = 4,100) the mean utility (95% confidence interval) for random effects model was 0.83 (0.78, 0.89); for TNM 0-1 0.85 (0.75, 0.95); for TNM II 0.85 (0.78, 0.93); for TNM III 0.83 (0.77, 0.90) and for TNM IV 0.73 (0.63, 0.82).The utility of patients in State P (first year after primary breast cancer) 0.84 (0.80, 0.88); in State R (first year after recurrence) 0.73 (0.69, 0.76), in State S (second and following years after primary breast cancer or recurrence) 0.88 (0.83, 0.92); and in State M (metastatic disease) 0.78 (0.74, 0.82). Mean utility for duration since diagnosis 13 to 36 months was 0.88 (0.80, 0.96, I2 =95%); for 37 to 60 months 0.89 (0.82, 0.96, I2 =90%); for more than 60 months 0.86 (0.76, 0.96, I2 =90%). Mean utility for chemotherapy was 0.86 (0.79, 0.92, I2 =97%); for radiotherapy 0.83 (0.69, 0.96, I2 =97%); surgery 0.80 (0.69, 0.91, I2 =98%); concurrent chemo-radiation 0.70 (0.60, 0.81, I2 =86%) and endocrine therapy 0.90 (0.83, 0.97, I2 =91%). Conclusion: This study synthesises the evidence for health state utility values for Chinese women with breast cancer which is useful to inform cost utility models.

Download Full-text